The positive experience of using a growth factor product on deep wounds with exposed bone.
Trafermin, a form of basic fibroblast growth factor, has been used in Japan since 2001. This study investigates whether it can facilitate closure in wounds with deep soft-tissue defects and exposed bone, where surgical closure is not possible.
Ichioka
S
S
Department of Plastic and Reconstructive Surgery, Saitama Medical School, Saitama, Japan. ichioka-stm@umin.ac.jp
Ohura
N
N
Nakatsuka
T
T
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001842:Bone and Bones; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000601:surgery; D017719:Diabetic Foot / Q000150:complications; D005142:Eyelid Neoplasms / Q000150:complications / Q000601:surgery; D005260:Female; D005346:Fibroblast Growth Factors / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000008:administration & dosage*; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects*; D014947:Wounds and Injuries / Q000188:drug therapy* / Q000209:etiology / Q000451:nursing
D010446:Peptide Fragments; C114444:trafermin; D005346:Fibroblast Growth Factors